Home » Topics » BioWorld Science

BioWorld Science
RSS

GlaxoSmithKline presents leucine-rich repeat serine/threonine-protein kinase 2 inhibitors

Aug. 24, 2018

Preclinical data and structure described for next-generation TYK2 inhibitor PF-06826647

Aug. 24, 2018

Lenvima approved in Europe as first-line treatment in adults with advanced or unresectable HCC

Aug. 24, 2018

Toca 5 pivotal phase III study of Toca-511/Toca-FC continues without modification

Aug. 24, 2018

Amgen targets the apelin receptor with AMG-986 for heart failure therapy

Aug. 24, 2018

DA-9701 may improve gastric motility in Parkinson's disease patients

Aug. 24, 2018

Liver-targeted prodrug may prove effective in fibrosis

Aug. 24, 2018

KW-6356 affects motor scores in phase II early Parkinson's disease trial

Aug. 24, 2018

Wee1 is a target in rhabdomyosarcoma

Aug. 24, 2018

Gene therapy for dominant blindness

Aug. 24, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...